Calibration of prior variance in the Bayesian continual reassessment method

Statistics in Medicine

Volumn 30, Issue 17, 2011, Pages 2081-2089

  Lee, Shing M ^a   Cheung, Ying Kuen ^a  

^a Columbia University ^*  (United States)

Author keywords

Dose finding; Indifference interval; Least informative prior; Phase I clinical trials

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DAUNORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANALYSIS OF VARIANCE; ARTICLE; BAYES THEOREM; CALIBRATION; CONTINUAL REASSESSMENT METHOD; DOSE CALCULATION; HUMAN; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NORMAL DISTRIBUTION; PROBABILITY; STUDY DESIGN;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; BORONIC ACIDS; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOMA, B-CELL; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; PYRAZINES;

EID: 79959930122     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4139     Document Type: Article

References (12)

1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46:33-48.
2. Chevret S. The continual reassessment method in cancer phase I clinical trials: a simulation study. Statistics in Medicine 1993; 12:1093-1108.
3. Paoletti X, Kramar A. A comparison of model choices for the continual reassessment method in phase I cancer trials. Statistics in Medicine 2009; 28:3012-3028.
4. Yin G, Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association 2009; 104:954-968.
5. Lee SM, Cheung YK. Model calibration in the continual reassessment method. Clinical Trials 2009; 6:227-238.
6. Cheung YK, Chappell R. A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics 2002; 58:671-674.
7. Leonard JP, Furman RR, Cheung YKK, Feldman EJ, Cho HJ, Vose JM, Nichols G, Glynn PW, Joyce MA, Ketas J, Ruan J, Carew J, Niesvizky R, LaCasce A, Chadburn A, Cesarman E, Coleman M. Phase I/II trial of bortezomib plus CHOP-Rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results. Blood 2005; 106:147A, 491 Part 1.
8. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset-toxicities. Biometrics 2000; 56:1177-1182.
9. Cheung YK. Coherence principles in dose-finding studies. Biometrika 2005; 92:863-873.
10. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2008.
11. Cheung YK. dfcrm: Dose-finding by the continual reassessment method. R package version 0.1-1. Available from:, 2008.
12. O'Quigley J, Shen L. Continual reassessment method: a likelihood approach. Biometrics 1996; 52:673-684.